Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registryPasquale Paolisso, Carmine Pizzi, Emanuele Barbato et al.|Cardiovascular Diabetology|2022Cited by 206
A selective microRNA-based strategy inhibits restenosis while preserving endothelial functionGaetano Santulli, Hana Totary-Jain|Journal of Clinical Investigation|2014Cited by 177
Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT RegistryPasquale Paolisso, Emanuele Barbato, Luca Bergamaschi et al.|Pharmacological Research|2022Cited by 146
A small-molecule allosteric inhibitor of BAX protects against doxorubicin-induced cardiomyopathyDulguun Amgalan, Richard N. Kitsis, Thomas P. Garner et al.|Nature Cancer|2020Cited by 123
In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-I AMI PROTECT studyArturo Cesaro, Raffaele Marfella, Felice Gragnano et al.|Frontiers in Cardiovascular Medicine|2022Cited by 87